{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:16:34Z","timestamp":1793373394298,"version":"4.5.0"},"reference-count":71,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T00:00:00Z","timestamp":1733616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:p>Antibody\u2010based therapeutic proteins (TPs) emerged as a promising therapeutic modality for chronic inflammatory diseases. During clinical development, the impact of disease on pharmacokinetics (PK) should be carefully considered to reliably extrapolate PK from healthy volunteers (HVs) in early\u2010phase studies to patients in later\u2010phase studies. This paper aimed to provide an overview of the impact of chronic inflammatory diseases on the PK of antibody\u2010based TPs. A literature search was conducted on Drugs@FDA and PubMed, yielding 30 TPs with author\u2010drawn conclusions about PK differences between HVs and patients with inflammatory diseases. Nine out of 30 TPs suggested PK differences in patients with inflammatory diseases compared with HVs, and patients mostly appeared to have higher drug clearance or lower drug exposure compared with HVs. However, the remaining 21 TPs appeared to have no apparent PK differences between patients and HVs. Based on ratios of reported drug clearance in patients vs. HVs (N: 31 ratios for 22 TPs), the difference in TP clearance due to inflammatory diseases did not exceed twofold (mean clearance ratio: 1.23; standard deviation: 0.25), with the most noticeable difference (&gt;50% higher clearance) observed in patients with inflammatory bowel diseases and rheumatoid arthritis. Covariate assessment in published population PK models of TPs revealed that higher baseline C\u2010reactive proteins and lower baseline albumin levels tend to be correlated with higher TP clearance. Future investigation is necessary to further elucidate the mechanism behind the inflammatory disease\u2010mediated PK differences.<\/jats:p>","DOI":"10.1002\/cpt.3513","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T07:05:34Z","timestamp":1733727934000},"page":"646-658","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Impact of Chronic Inflammatory Diseases\u00a0on Clinical Pharmacokinetics of Antibody\u2010Based Therapeutic Proteins"],"prefix":"10.1002","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1594-6387","authenticated-orcid":false,"given":"Xiaofan","family":"Tian","sequence":"first","affiliation":[{"name":"Translational Medicine and Clinical Pharmacology Boehringer Ingelheim Pharmaceuticals Inc.  Ridgefield Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6217-5442","authenticated-orcid":false,"given":"Yichao","family":"Yu","sequence":"additional","affiliation":[{"name":"Translational Medicine and Clinical Pharmacology Boehringer Ingelheim Pharmaceuticals Inc.  Ridgefield Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshith","family":"Neeli","sequence":"additional","affiliation":[{"name":"Translational Medicine and Clinical Pharmacology Boehringer Ingelheim Pharmaceuticals Inc.  Ridgefield Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilara","family":"Jappar","sequence":"additional","affiliation":[{"name":"Translational Medicine and Clinical Pharmacology Boehringer Ingelheim Pharmaceuticals Inc.  Ridgefield Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,12,8]]},"reference":[{"key":"e_1_2_10_1_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-019-0592-z"},{"key":"e_1_2_10_2_1","unstructured":"CHMP.Guideline on clinical investigation of the pharmacokinetics of therapeutic proteins<https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/guideline\u2010clinical\u2010investigation\u2010pharmacokinetics\u2010therapeutic\u2010proteins_en.pdf> (2007)."},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.121.000463"},{"key":"e_1_2_10_4_1","doi-asserted-by":"crossref","unstructured":"Waldmann T.A. Strober W.&Blaese R.M.Progress in Immunology.XII: Biol Funct Differ Cl IMMUNOGLOBULIN1971:891\u2013903.https:\/\/doi.org\/10.1016\/b978\u20100\u201012\u2010057550\u20103.50072\u20107.","DOI":"10.1016\/B978-0-12-057550-3.50072-7"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12224"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12567"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1014414520282"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/antib8040056"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011413894"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13641"},{"key":"e_1_2_10_11_1","volume-title":"Infliximab [package insert]","year":"2013"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.328"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.10.029"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0718-4"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.06.002"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030452"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15364"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12589"},{"key":"e_1_2_10_19_1","unstructured":"U.S. Food and Drug Administration.Sarilumab BLA 761037\/Clinical Pharmacology Review<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761037Orig1s000ClinPharmR.pdf> (2015)."},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1216741"},{"key":"e_1_2_10_21_1","unstructured":"U.S. Food and Drug Administration.Spesolimab BLA 761244\/ Multi\u2010Disciplinary Review and Evaluation<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2022\/761244Orig1s000MultidisciplineR.pdf> (2022)."},{"key":"e_1_2_10_22_1","unstructured":"U.S. Food and Drug Administration.Golimumab BLA 125289\/Clinical Pharmacology Review<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/125289s000_ClinPharmR_P1.pdf> (2009)."},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0225-3"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13243"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101587"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14330"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(05)03638-X"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004272731"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14364"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2831"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00743-7"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.12924"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13270"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-020-00978-4"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0191-7"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1545"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/132.7.1921"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.s1-6.1.13"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2301594"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1515\/cclm.1992.30.4.197"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.016"},{"key":"e_1_2_10_42_1","unstructured":"European Medicines Agency.Guideline on Immunogenicity Assessment of Biotechnology\u2010Derived Therapeutic Proteins. Revision 1<https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/guideline\u2010immunogenicity\u2010assessment\u2010therapeutic\u2010proteins\u2010revision\u20101_en.pdf> (2017)."},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14207"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04477.x"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1401"},{"key":"e_1_2_10_46_1","unstructured":"U.S. Food and Drug Administration.Dupilumab BLA 761055\/Clinical Pharmacology Review<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761055Orig1s000ClinPharmR.pdf> (2017)."},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1113"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/145947"},{"key":"e_1_2_10_49_1","unstructured":"U.S. Food and Drug Administration.Mepolizumab BLA 125526\/Clinical Pharmacology Review<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/125526Orig1s000ClinPharmR.pdf> (2015)."},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04334.x"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0797-9"},{"key":"e_1_2_10_52_1","unstructured":"U.S. Food and Drug Administration.Natalizumab BLA 125104\/Clinical Pharmacology Review<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/125104s000_Natalizumab_Biopharmr.pdf> (2004)."},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.334"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00759-z"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2009.13"},{"key":"e_1_2_10_56_1","volume-title":"Abatacept [package insert]","year":"2023"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1101"},{"key":"e_1_2_10_58_1","volume-title":"Adalimumab [package insert]","year":"2021"},{"key":"e_1_2_10_59_1","unstructured":"U.S. Food and Drug Administration.Tocilizumab BLA 125276\/Clinical Pharmacology Review<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/125276s000ClinPharmR.pdf> (2010)."},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010375961"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-020-09688-y"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0586-5"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315574558"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.2165\/11599820-000000000-00000"},{"key":"e_1_2_10_65_1","volume-title":"Certolizumab pegol [package insert]","year":"2018"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14361"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1068"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.491"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0502-4"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.11.010"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12313"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.3513","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T21:18:49Z","timestamp":1740345529000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.3513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,8]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["10.1002\/cpt.3513"],"URL":"https:\/\/doi.org\/10.1002\/cpt.3513","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,8]]},"assertion":[{"value":"2024-08-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}